ICMJE Form for Disclosure of Potential Conflicts of Interest

Similar documents
ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Uniform Disclosure Form for Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest

INTERNATIONAL COMMITTEE 9/ MEDICAL [OURNAL EDITORS

ICMJE Form for Disclosure of Potential Conflicts of Interest

All authors of papers submitted to (name of journal) must complete this form and disclose any real or perceived conflict of interest.

IeMJE~iA~~1~1 J~~~~tl'~g;;'g'~

Conflict of Interest Management Plan. You disclosed one or more significant financial interest(s) related to your university responsibilities.

UA Policy on Conflict of Interest/Financial Disclosure in Research and Other Sponsored Programs (revised August 2012) FREQUENTLY ASKED QUESTIONS

UC Davis Policy and Procedure Manual

Investigator s Disclosure of Economic Interests Addendum

Financial Conflicts of Interest in Research: Putting the Pieces Together

RESEARCH CONFLICT OF INTEREST. Vyju Ram, MD Conflict of Interest Program

Please scroll through and complete the entire form! Your application will not be accepted if all areas highlighted in yellow are not complete.

Conflict of Interest with Grants Policy DRAFT

CALIFORNIA STATE UNIVERSITY LOS ANGELES. for PROJECTS FUNDED BY THE PUBLIC HEALTH SERVICE (PHS)

Florida International University Herbert Wertheim College of Medicine Industry Relations Policy and Guidelines 2/16/15

Letter of Intent to Establish a Consortium Agreement Saint Louis University as Primary Applicant

Section 1 Conflicts of Interest Introduction

UTAH VALLEY UNIVERSITY Policies and Procedures

Financial Conflict of Interest Promoting Objectivity in Research Policy

MARICOPA COUNTY COMMUNITY COLLEGE DISTRICT STANDARDS FOR FINANCIAL DISCLOSURE TO AVOID CONFLICT OF INTEREST IN FEDERALLY-FUNDED PROJECTS

XAVIER UNIVERSITY. Financial Conflict of Interest Policy-Federal Grant Proposals

FINANCIAL CONFLICT OF INTEREST POLICY Public Health Services SECTION 1 OVERVIEW, APPLICABILITY AND RESPONSIBILITIES

Intellectual Property Policy: Purpose. Applicability. Definitions

SEATTLE CHILDREN S RESEARCH INSTITUTE OPERATING POLICIES / PROCEDURES

ALLEGHENY GENERAL HOSPITAL Pittsburgh, Pennsylvania

Financial Conflict of Interest Training

2014 Breast Cancer Symposium September 4 6, 2014 San Francisco, CA

GUIDELINES FOR INTERACTIONS OF CLINICIANS AND RESEARCHERS WITH INDUSTRY

Daiichi Sankyo Group Global Marketing Code of Conduct

Your role in the CME Activity: Presenter Author Planning Committee Moderator Program Director. Title of CME Activity: Activity Date:

1. Employment, Consulting, Product Development (Design Team/Royalty-based Contracts) and Research Arrangements with a Commercial Orthopaedic Company

UMass Memorial Medical Center Policy 1143 Vendor Relationships

POLICY: Conflict of Interest

2 nd Annual MedStar Washington Hospital Center Nursing Evidence-Based-Practice & Research Conference

Request to Use an External IRB as an IRB of Record

Conflict of Interest Policy Texas Lutheran University

Grant Administration Glossary of Commonly-Used Terms in Sponsored Programs

LETTER OF INTENT INSTRUCTIONS

Charles A. King Trust Postdoctoral Research Fellowship Program

Biomedical Research Grant (RG) Program Description

CANCER COUNCIL NSW PROGRAM GRANTS PEER REVIEW GUIDELINES

ACCME Data Request Form 792_ Page 1 of 8

Damon Runyon-Sohn Pediatric Cancer Fellowship Award Award Statement

Approved by: UMMG Executive Committee. Date Approved: NOVEMBER 22, 2011

American Head & Neck Society

If there are any unanswered (Required) questions by the deadline, your LOI will be disqualified and rejected from the Challenge.

9 th National Conference on Cancer Nursing Research February 8 10, 2007 Hollywood, California. General Information

NAMI Illinois 2010 Annual Conference

ecoi Fast Start Guide

MEMBERSHIP AGREEMENT FOR THE ANALYTIC TECHNOLOGY INDUSTRY ROUNDTABLE

June 23, Dear Ms. Moreland:

Educational Grant Application

Two Submission Dates. January 4, 2018 June 28, 2018

THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (LATIN AMERICA EDITION)

Stand Up To Cancer T-Cell Lymphoma Dream Team Translational Research Grant Dream Team Translational Research Grant

Standard Operating Procedures for P209: Investigator Conflict of Interest Policy

TRIOLOGICAL SOCIETY AUTHOR FORM

Terms of Submission In order to participate, you must be at least eighteen (18) years old.

Dear Prospective Presenter:

Guiding Principle... 2

Authorized licensed use limited to: UNIVERSITA MODENA. Downloaded on November 10,2011 at 14:46:47 UTC from IEEE Xplore. Restrictions apply.

NOVA SOUTHEASTERN UNIVERSITY OFFICE OF SPONSORED PROGRAMS POLICIES AND PROCEDURES

Conflict of Interest/Commitment

Children s Discovery Institute Grants Policies

> TITLE 13. LAW AND PUBLIC SAFETY

Option 1 We are a physician organization that is planning this educational event alone or in conjunction with another physician organization.

Allergic Respiratory Disease Award (AI) Program Description

SECTION PROPOSAL FOR EDUCATION ACTIVITY:

27th Annual Holiday Knee and Hip Course December 3-5, 2015 The Grand Hyatt New York City, NY

Financial Conflict of Interest Management Plan

The Patrick and Catherine Weldon Donaghue Foundation for Medical Research POLICIES FOR GRANTEES

UNIVERSITY OF DELAWARE RESEARCH FOUNDATION (UDRF)

Physician/Industry Contacts: Updated Focus on CME & Grassley Looks at Possible Research Conflicts

Financial Conflict of Interest Policy

What next for Life Sciences? Vir Lakshman

Compliance Policy C-FMS Clinical Research Project Approval Application

RESEARCH GRANT PROGRAM INFORMATION

Collaborative Operations and Services Grant Program GUIDELINES Revised January 15, 2014

Submit to JCO Precision Oncology (JCO PO) and have your precision oncology research make an impact with the world's oncologists and their patients.

The University of Utah

education continuing CARRELL-KRUSEN NEUROMUSCULAR SYMPOSIUM 33 rd ANNUAL Thursday-Friday, February 17-18, 2011

Standard terms and conditions for grants from FHF

Alfred E. Mann Foundation for Biomedical Engineering

Alpha-1 Foundation Letter of Intent and Full Application Instructions

ASSOCIATION FOR ACCESSIBLE MEDICINES Code of Business Ethics. March 2018

PATIENT REGISTRATION FORM (ecw)

CureSearch Acceleration Initiative 2 (AI-2) International Grand Challenge Awards in Pediatric Cancer

Transcription:

Instructions The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts. 1. 2. 3. Identifying information. The work under consideration for publication. This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes". Relevant financial activities outside the submitted work. This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer. Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so. For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company. 4. 5. Intellectual Property. This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties. Relationships not covered above. Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work. Definitions. Entity: government agency, foundation, commercial sponsor, academic institution, etc. Grant: A grant from an entity, generally [but not always] paid to your organization Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc. Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Royalties: Funds are coming in to you or your institution due to your patent 1

Section 1. Identifying Information 1. Given Name (First Name) Aaron 2. Surname (Last Name) 3. Date 13-April-2016 4. Are you the corresponding author? Yes No 5. Manuscript Title Diabetic Sensory and Motor Neuropathy 6. Manuscript Identifying Number (if you know it) 15-03948 Section 2. The Work Under Consideration for Publication Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest? Yes No Section 3. Relevant financial activities outside the submitted work. Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication. Are there any relevant conflicts of interest? Yes No If yes, please fill out the appropriate information below. Name of Entity Grant? Personal Fees? Non-Financial Support? Other? Comments Merck Consulting/Advisory Board/Speaker IONIS Pharmaceuticals Consulting Pfizer Consulting Daiichi-Sankyo Consulting/Advisory Board Neurometrix Consulting/Advisory Board Santarus Pharmaceuticals Consulting Nestle Health Science - Pamlab Consulting/Speaker 2

Name of Entity Medikinetics Grant? Personal Fees? Non-Financial Support? Other? Comments Consulting Ipsen Pharmaceuticals Consulting/Advisory Janssen Pharmaceuticals Consulting Bayer Consulting Astellas Consulting/Advisory Alnylam Consulting Daiichi Sankyo Research Grant Pfizer, Inc. Research Grant Tercica, Inc. Research Grant ViroMed Research Grant Intarcia Research Grant Impeto Medical Research Grant Veroscience Research Grant Novo Nordisk Research Grant Cline Davis and Mann Consulting System Analytic Inc. Consulting Section 4. Intellectual Property -- Patents & Copyrights Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No 3

Section 5. Relationships not covered above Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work? Yes, the following relationships/conditions/circumstances are present (explain below): No other relationships/conditions/circumstances that present a potential conflict of interest In the interest of disclosure of "broadly relevant" association readers could perceive to have influenced or give the appearance of influencing what was written I wish to draw attention to the following: Dr. reports having received royalties for the use of the Norfolk QOLDN tool, a quality-of-life instrument that he codeveloped for use in clinical trials in patients with diabetic neuropathy. The tool is owned by Eastern Virginia Medical School and is freely available to academic institutions but requires licensing by industry. Dr. also reports that he is the inventor of a supplement that includes a mixture of alpha lipoic acid, methylcobalamin, benfotiamine, dihomo-gamma-linoleic acid, cholecalciferol, and ascorbic acid, the rights to which were assigned to his medical school. Dr. reports that he, his laboratory, and his department have not and will not receive any income that might derive from this product. At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships. Section 6. Disclosure Statement Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below. Dr. reports personal fees from Merck, personal fees from IONIS Pharmaceuticals, personal fees from Pfizer, personal fees from Daiichi-Sankyo, personal fees from Neurometrix, personal fees from Santarus Pharmaceuticals, personal fees from Nestle Health Science - Pamlab, personal fees from Medikinetics, personal fees from Ipsen Pharmaceuticals, personal fees from Janssen Pharmaceuticals, personal fees from Bayer, personal fees from Astellas, personal fees from Alnylam, grants from Daiichi Sankyo, grants from Pfizer, Inc., grants from Tercica, Inc., grants from ViroMed, grants from Intarcia, grants from Impeto Medical, grants from Veroscience, grants from Novo Nordisk, personal fees from Cline Davis and Mann, personal fees from System Analytic Inc., outside the submitted work. Dr. reports having received royalties for the use of the Norfolk QOLDN tool, a quality-of-life instrument that he codeveloped for use in clinical trials in patients with diabetic neuropathy. The tool is owned by Eastern Virginia Medical School and is freely available to academic institutions but requires licensing by industry. Dr. also reports that he is the inventor of a supplement that includes a mixture of alpha lipoic acid, methylcobalamin, benfotiamine, dihomo-gamma-linoleic acid, cholecalciferol, and ascorbic acid, the rights to which were assigned to his medical school. Dr. reports that he, his laboratory, and his department have not and will not receive any income that might derive from this product. 4

Evaluation and Feedback Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form. 5